Investment
Features
FeesSafety
Academy
More
Pluang+

Compare State Street SPDR Bloomberg High Yield Bond ETF (JNK) vs Novartis AG (NVS) Price & Performance

State Street SPDR Bloomberg High Yield Bond ETFTrade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

State Street SPDR Bloomberg High Yield Bond ETF vs Novartis AG — how do they compare? State Street SPDR Bloomberg High Yield Bond ETF trades at $95.88, while Novartis AG trades at $152.69 (market cap $295.37B). The key difference: Novartis AG pays a 3.07% dividend while State Street SPDR Bloomberg High Yield Bond ETF pays none, and Novartis AG is trading nearer its 52-week high, State Street SPDR Bloomberg High Yield Bond ETF nearer its low. Which is the better fit depends on your goals.

JNKNVS
Sector
Fixed IncomeHealth
52-Week High
$98.19$168.62
52-Week Low
$94.66$119.31
Market Cap
$295.37B
Enterprise Value
$336.69B
Dividend Yield
3.07%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

State Street SPDR Bloomberg High Yield Bond ETF

JNK trades at $95.875, up 0.24% with a bearish technical signal from moving averages. Dividend payments of $0.52-$0.53 are scheduled through August 2026. Recent news highlights risks from AI-related corporate debt and rising oil prices affecting bond yields.

The outlook is cautious due to credit market risks and inflation concerns. Opportunities exist for income-focused investors from dividends, but volatility from Fed policy and geopolitical tensions poses significant downside risks.

Novartis AG

Novartis AG (NVS) trades at $152.54, down 2.71% on the day, with a neutral technical signal. The company reported strong Q2 2026 earnings, beating EPS estimates of $2.17 with $2.41 actual, driven by oncology drug performance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%. Analyst consensus is mixed with 24% buy, 68% hold, and 8% sell ratings among 25 analysts.

The outlook is cautiously optimistic, supported by a robust drug pipeline and recent earnings strength, but risks include generic competition pressure on key drugs like Entresto and rising debt levels. The stock presents a stable investment opportunity with solid profitability, though growth may be tempered by industry headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About State Street SPDR Bloomberg High Yield Bond ETF

JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.

Read more on JNK

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS